Autor: "Karolin Isaksson" - OpacWWW

Skocz do pozycji: 8 8.

Tytuł :: Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
Autorzy :: Olofsson Bagge R; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Kicinski M; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Faries MB; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Gyorki DE; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Isaksson K; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Katsarelias D; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Lo S; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Moncrieff M; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Spillane A; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Suciu S; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
van Akkooi A; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Sep 20; Vol. 38 (27), pp. 3233-3234. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :: Letter
: Opinia redakcyjna

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Karolin Isaksson"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu